AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...
Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. What next for ...
Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...
In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...
Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...
Zacks Investment Research on MSN
PFE market cap falls more than $7B in a month: How to play the stock
Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...
Tempus AI stock contract value exceeds $1.1B with 70 pharma deals. Diagnostics revenue up 111%, data segment up 31% in 2025 ...
Citigroup (NYSE:C) used its fourth-quarter 2025 earnings call to highlight a “strong quarter” and what CEO Jane Fraser ...
Get the latest Ind-Swift Laboratories share price today on NSE & BSE. Explore Ind-Swift Laboratories stock analysis, financial performance, market capitalization, dividend history, and future outlook ...
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback